Neumora TherapeuticsNMRA
About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Employees: 108
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
258% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 12
127% more call options, than puts
Call options by funds: $1.81M | Put options by funds: $797K
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
8% more funds holding
Funds holding: 86 [Q1] → 93 (+7) [Q2]
7.13% more ownership
Funds ownership: 33.08% [Q1] → 40.21% (+7.13%) [Q2]
13% less capital invested
Capital invested by funds: $724M [Q1] → $630M (-$93M) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Needham Ami Fadia 59% 1-year accuracy 57 / 96 met price target | 39%upside $23 | Buy Reiterated | 18 Oct 2024 |
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 61 / 121 met price target | 82%upside $30 | Buy Initiated | 1 Oct 2024 |
Needham Ami Fadia 59% 1-year accuracy 57 / 96 met price target | 39%upside $23 | Buy Reiterated | 12 Sept 2024 |
RBC Capital Brian Abrahams 59% 1-year accuracy 27 / 46 met price target | 76%upside $29 | Outperform Reiterated | 4 Sept 2024 |
Needham Ami Fadia 59% 1-year accuracy 57 / 96 met price target | 39%upside $23 | Buy Reiterated | 7 Aug 2024 |